Ustekinumab - Janssen Biotech

Drug Profile

Ustekinumab - Janssen Biotech

Alternative Names: Anti-interleukin-12 p40 monoclonal antibody; CNTO-1275; STELARA; Stelara; Stellara; Sterrara; Suterara

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriatic arthritis
  • Phase III Spondylarthritis; Systemic lupus erythematosus; Ulcerative colitis
  • Phase II Atopic dermatitis
  • Discontinued Multiple sclerosis; Palmoplantar pustulosis; Primary biliary cirrhosis; Rheumatoid arthritis; Sarcoidosis

Most Recent Events

  • 09 Oct 2018 Adverse events and efficacy data from the phase III trial in Ulcerative colitis released by Janssen
  • 10 Jul 2018 Efficacy and adverse events data from a phase II trial in Systemic lupus erythematosus presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 26 Jun 2018 Launched for Plaque psoriasis in China (SC) before June 2018 (Xian Janssen website, June 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top